Renal Cell Carcinoma AND Urothelial Malignancy

The answer first

Renal cell carcinoma (RCC) and urothelial malignancy are the two most common genitourinary cancers seen by the physician, and both have undergone a therapeutic revolution driven by immune checkpoint inhibition and tyrosine kinase-targeted therapy. RCC presents classically with haematuria, flank pain, and a mass (the classic triad in about 10 percent), but more often as an incidental finding on imaging, with paraneoplastic syndromes (polycythaemia, hypercalcaemia, Stauffer syndrome), or with metastatic disease. Urothelial malignancy presents with painless visible haematuria, irritative lower urinary tract symptoms, or as an upper tract lesion with flank pain and weight loss. The physician's task is to recognise the presentation, stage the disease, and integrate surgical, oncological, and supportive therapy across the RCC (clear cell predominant; papillary, chromophobe variants) and urothelial (bladder and upper tract) disease spectra. ^{[1] [6]}

The FRACP candidate must be able to defend three positions without hedging: (1) any visible haematuria is urothelial malignancy until proven otherwise and mandates upper tract imaging (CT urogram) plus cystoscopy; (2) the standard initial therapy for localised RCC is partial or radical nephrectomy, while advanced clear cell RCC is treated with combination immune checkpoint inhibitor therapy (ipilimumab plus nivolumab) or a tyrosine kinase inhibitor plus checkpoint inhibitor combination; and (3) urothelial carcinoma of the bladder is treated with transurethral resection (with intravesical BCG or chemotherapy for high-risk non-muscle-invasive disease), radical cystectomy or chemoradiotherapy for muscle-invasive disease, and platinum-based chemotherapy plus checkpoint inhibitor therapy for metastatic disease. Lead with the decision, then the evidence, then the trap. ^{[1] [2]}

References9ShowHide

1. [1]Chen YS, Yu CC, Chang R, Wu SH, et al. Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease Cancer Immunol Immunother, 2026.PMID 42426360
2. [2]Petrelli F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al. Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings Curr Oncol Rep, 2026.PMID 42406187
3. [3]Zhang Y, Wu G, Sun F, Wang B, et al. Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making Front Oncol, 2026.PMID 42404222
4. [4]Jost LM, Duwe G, Kauth V, Höfner T, et al. [Artificial intelligence as decision support tool in urological oncology: current evidence and challenges] Urologie, 2026.PMID 42126599
5. [5]Inoue S, Tsuboi I, Miszczyk M, Miyajima K, et al. Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis JAMA Netw Open, 2026.PMID 42084869
6. [6]Maráz A, Koroncziová K, Rozsvai T [Immunotherapy for urological cancers in 2025] Magy Onkol, 2025.PMID 41385769
7. [10]Loughraieb S, Guendouzi R, Terki F, Mokeddem K, et al. Invasive Renal Parenchymal Urothelial Carcinoma: A Case Report and Literature Review of Imaging Features and Spectrum of Infiltrative Renal Masses Cureus, 2026.PMID 42299196
8. [11]Luo W, Song Z, Liu Z, Zhang G, et al. Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma J Exp Clin Cancer Res, 2026.PMID 42469889
9. [12]Wang B, Liu H, Guo Y, Ma J, et al. Multi-omics profiling highlights RPLP0 as a potential biomarker for prognosis and response to immunotherapy in clear cell renal cell carcinoma BMC Cancer, 2026.PMID 42469699